Ligand Pharmaceuticals INC

Ligand Pharmaceuticals announced robust second-quarter 2026 financial results, highlighted by a 32% year-over-year increase in royalty revenue and the successful acquisition of XOMA Royalty.

Ligand Pharmaceuticals has finalized its acquisition of XOMA Royalty Corporation for approximately $739 million, significantly expanding its biopharmaceutical royalty asset portfolio.

Ligand Pharmaceuticals has finalized a $700 million private offering of 0.00% convertible senior notes due 2031.

Ligand Pharmaceuticals Incorporated announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and approval of an amended stock incentive plan.

Ligand Pharmaceuticals Incorporated announced an amendment to its Agreement and Plan of Merger with XOMA Royalty Corporation, adding a new holding company as a party to the agreement.

Ligand Pharmaceuticals announced strong first quarter 2026 financial results, driven by a 56% year-over-year increase in royalty revenue, and reaffirmed its full-year guidance, incorporating the anticipated contribution from the pending acquisition of XOMA Royalty.

Ligand Pharmaceuticals Inc. announced a significant increase in total revenue and income for the second quarter of 2026, driven by robust royalty growth and strategic financial activities.

Ligand Pharmaceuticals reported a significant increase in Q3 2025 revenue, driven by the Pelthos Transaction and strong royalty growth, alongside new strategic investments and a convertible senior notes offering.

Ligand Pharmaceuticals reported a significant increase in Q2 2025 royalties and total revenue, driven by new financial royalty assets and strong product sales, alongside key strategic investments and divestitures.

Ligand Pharmaceuticals reports a net loss for Q1 2025, driven by a significant increase in research and development expenses, while also announcing a merger agreement for its Pelthos Therapeutics subsidiary.

Ligand Pharmaceuticals' Q3 2024 revenue increased by 58% year-over-year, driven by strong royalty income and milestone payments, despite a decrease in Captisol sales.

Ligand Pharmaceuticals' Q2 2024 results show a significant increase in revenue but also a substantial net loss due to a financial royalty asset impairment, alongside strategic acquisitions and portfolio advancements.

Ligand Pharmaceuticals reports significant revenue growth in 2025, driven by its biopharmaceutical royalty aggregation strategy and key product performance, alongside strategic investments and a strong cash position.

Ligand Pharmaceuticals' FY 2024 results showcase a 27% revenue increase driven by royalty growth and strategic acquisitions, alongside key investments in pipeline expansion.

Ligand Pharmaceuticals has amended its development funding agreement with Palvella Therapeutics, providing additional funding and securing options for future product revenue streams.

Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals Inc, sold 31,641 shares of common stock on August 12, 2026 for $292.06 per share.

Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals Inc, sold 5,000 shares of common stock on August 3, 2026.

Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals Inc., reported transactions involving common stock and employee stock options.

Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals Inc., acquired 17 shares of common stock through the company's Employee Stock Purchase Plan.

Todd C. Davis, CEO and Director of Ligand Pharmaceuticals, acquired 132 shares of common stock through the Ligand Employee Stock Purchase Plan.

Stephen L. Sabba, a Director at Ligand Pharmaceuticals Inc., reported transactions involving common stock and stock options on June 16, 2026.

Ligand Pharmaceuticals Incorporated announced its annual meeting of stockholders will be held virtually on June 5, 2026, to elect directors, ratify auditors, and approve executive compensation and equity plan amendments.

Ligand Pharmaceuticals Incorporated files a definitive proxy statement with the SEC.

Ligand Pharmaceuticals will hold its annual stockholder meeting virtually on June 6, 2025, to vote on director elections, auditor ratification, and executive compensation.

Ligand Pharmaceuticals clarifies the rationale behind its proposed equity plan amendment, emphasizing the impact of spin-out transactions and the need to retain key talent.

Ligand Pharmaceuticals issues a supplement to its proxy statement clarifying the voting standards for the approval of the amendment and restatement of its 2002 Stock Incentive Plan at the upcoming annual meeting.

Ligand Pharmaceuticals has filed a definitive proxy statement with the Securities and Exchange Commission.

Ligand Pharmaceuticals has entered into a definitive agreement to acquire XOMA Royalty Corporation for $39.00 per share in cash plus contingent value rights.

Ligand Pharmaceuticals has increased its beneficial ownership in Pelthos Therapeutics to 49.9% through a new $9.0 million senior secured convertible note financing.

Ligand Pharmaceuticals Incorporated has become a significant beneficial owner of Pelthos Therapeutics Inc., holding 49.9% of its common stock, following the completion of a merger and a private investment in public equity (PIPE) financing.

Invesco Ltd. has disclosed beneficial ownership of 6.1% of Ligand Pharmaceuticals Inc.'s common stock as of June 30, 2026.

The Vanguard Group reports 0% beneficial ownership of Ligand Pharmaceuticals Inc. common stock following an internal realignment.

Janus Henderson Group plc has reported a 5.3% beneficial ownership stake in Ligand Pharmaceuticals Incorporated common stock as of September 30, 2025.

BlackRock, Inc. has filed an Amendment No. 18 to Schedule 13G, disclosing a beneficial ownership of 14.5% in Ligand Pharmaceuticals Inc. common stock.

Janus Henderson Group plc has filed an Amendment No. 8 to its Schedule 13G, disclosing a 5.5% beneficial ownership stake in Ligand Pharmaceuticals Incorporated as of June 30, 2025.

Janus Henderson Group PLC has filed an Amendment No. 7 to its Schedule 13G, disclosing a 5.3% beneficial ownership stake in Ligand Pharmaceuticals Incorporated as of March 31, 2025.